Alpha 1 Biomedicals Inc. announced Monday that it hasenrolled the final patient in its Phase III clinical trial ofThymosin alpha 1 for treating chronic hepatitis B.
The patient will be treated for six months and then followedfor another six. The Phase III trials on Thymosin alpha 1,which is a synthetic version of the natural hormone, and mayact as an immunomodulator, started in February 1991.
The Bethesda, Md., company (NASDAQ:ALBM) expects to submita new drug application (NDA) with FDA by the end of 1994,according to Vincent Simmon, president and chief executiveofficer. -- Jennifer Van Brunt
(c) 1997 American Health Consultants. All rights reserved.